Treatment News : PrEP Adherence Varies Greatly Between Cities

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2014

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 28, 2014

PrEP Adherence Varies Greatly Between Cities

Adherence to the daily regimen of Truvada (tenofovir/emtricitabine) as pre-exposure prophylaxis (PrEP) against HIV infection varied widely in studies conducted in three different cities. Findings from the study were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston and reported by aidsmap.

A total of 1,059 gay or bisexual men or transgender women visiting sexual health clinics in San Francisco, Miami and Washington, DC, were offered the chance to be screened for eligibility to participate in an open-label trial of Truvada as PrEP.

Those who sought out the study of their own accord, as opposed to being referred by a doctor, were more likely to be white, have a higher level of education and to be both at high risk of HIV acquisition and to see themselves as at high risk.

The approximately 600 men and trans women who ultimately participated were 32 years old on average. Forty-eight percent of the cohort was white, 35 percent Latino and just 8 percent black.

The study investigators randomly selected about a third of the men to receive drug-level testing to determine their adherence to Truvada. Fifty-two percent of those in San Francisco had levels of the drug in their blood that indicated they were taking the drug daily as prescribed, compared with 35 percent of those in Washington and just 13.5 percent in Miami.

Forty-three percent of the participants in both Miami and Washington and 40 percent of those in San Francisco were apparently taking Truvada about four days a week, which research has suggested reduces the likelihood of HIV transmission by about 96 percent. Thus, 92 percent of the participants in San Francisco, 57 percent of those in Washington and 57 percent of those in Miami were probably protected against HIV acquisition by at least that factor.

The respective percentages of those taking two doses a week, which confers about 70 percent protection, were: 27 percent among Miamians and 4 percent among both Washingtonians and San Franciscans. The respective proportions that took one dose a week, which offers very little protection against HIV, were 11 percent, 2 percent and 4 percent. And finally, a respective 4.5 percent, 2 percent and zero did not have detectable levels of Truvada.

To read the aidsmap story, click here.

Search: Truvada, PrEP, pre-exposure prophylaxis, HIV, tenofovir, emtricitabine, aidsmap, Conference on Retroviruses and Opportunistic Infections, CROI.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.